Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 500, Issue 1-2, Pages 268-274Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2016.01.042
Keywords
Lipid-based nanoparticle; Skin disorder; RNA interference; Liposome; Topical drug delivery; Gene therapy
Categories
Funding
- BOF-project (Ghent University, Belgium) [01J10211T]
- TGO grant (IWT, Belgium) [120829]
Ask authors/readers for more resources
RNA interference (RNAi) is a rapidly emerging approach for targeted gene silencing to alleviate disease pathology. However, lack of efficient carriers for targeted delivery delays the clinical translation of RNAi. An interesting target for local RNAi therapeutics is the skin as it allows direct access to target cells. Still, applications are limited due to the effective skin barrier which hinders penetration. Herein, a description is given of a liposomal carrier, called 'DDC642', capable of delivering RNAi molecules to the epidermis of impaired and intact human skin, without targeting the dermis or circulatory system. In a psoriasis tissue model, down-regulation of the psoriasis marker human beta-defensin 2 by DDC642-delivered siRNA was confirmed, providing proof-of-concept. These liposomes thus hold great potential as topical delivery system for RNAi therapeutics in the treatment of numerous skin diseases. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available